ArticleOncotarget2015

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Zhen-Yu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.